OJEMDA (tovorafenib)

TherapyDay One Biopharmaceuticals, Inc.

OJEMDA (tovorafenib) from Day One Biopharmaceuticals is a RAF inhibitor used in pediatric low-grade glioma with relevant MAPK pathway alterations.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and OJEMDA. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where OJEMDA is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Low-Grade Glioma Solid Tumor · Brain	BRAF V600 and BRAF fusions		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for OJEMDA.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering OJEMDA for eligible patients.

Test

FoundationOne CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Tissue (FFPE)

1 approvalView test profile →

This view is scoped to OJEMDA (tovorafenib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.